Rosuvastatin: A high-potency HMG-CoA reductase inhibitor

Journal of the American Pharmacists Association

Volumn 45, Issue 4, 2005, Pages 503-513

  Lopez, Larry M ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Atorvastatin; Cholesterol; Dyslipidemia; Hyperlipidemia; Pravastatin; Review; Rosuvastatin; Simvastatin

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; STATIN; TRIACYLGLYCEROL; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MEDLINE; REVIEW; UNSPECIFIED SIDE EFFECT; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; TREATMENT OUTCOME;

CHOLESTEROL, LDL; DYSLIPIDEMIAS; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MOLECULAR STRUCTURE; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 33645882200     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/1544345054475522     Document Type: Review

References (43)

1. Lopez LM. Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors. Am J Health Syst Pharm. 2002;59:1173-9.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
3. Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-7.
4. Sacks FM, Pfeffer MA, Moyé LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-9.
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-22.
6. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-57.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 〈Adult Treatment Panel III〉. Final report. Circulation. 2002;106:3143-421.
9. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601-10.
10. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-67.
11. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses 〈STELLAR Trial〉. Am J Cardiol. 2003;92:152-60.
12. Crestor 〈rosuvastatin calcium〉 tablets [package insert]. Wilmington, Del.: AstraZeneca Pharmaceuticals LP; March 2005.
13. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87(suppl):28B-32B.
14. Davidson MH. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 2002;11:125-41.
15. McKenney JM. Pharmacologic characteristics of statins. Clin Cardiol. 2003;26 (suppl III):III-32-8.
16. Chong PH, Yim BT. Rosuvastatin for the treatment of patients with hypercholesterolemia. Ann Pharmacother. 2002;36:93-101.
17. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 2003;25:2553-63.
18. Olsson AG, Pears J, McKellar J, et al. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 2001;88:504-8.
19. Saito Y, Goto Y, Dane A, Strutt K. Randomized, double-blind, placebo-controlled, dose-ranging study of rosuvastatin in Japanese hypercholesterolemic subjects [abstract]. Atherosclerosis. 2002;3(suppl):1999.
20. Schuster H. Study Group on behalf of mercury. Effects of switching to rosuvastatin from atrovastatin or other statins on achievement of international low-density lipoprotein cholesterol goals: Mercury I trial [abstract]. J Am Coll Cardiol. 2003;41:227-8.
21. Schuster H, Cheung, Bonnet J, et al. Switching to rosuvastatin from other statins has beneficial effects on lipid ratios [abstract]. Atherosclerosis. 2003;4(suppl):81.
22. Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 2002;:144:1044-51.
23. Brown WV, Bays HE, Hassman DR, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J. 2002;144:1036-43.
24. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002;89:268-75.
25. Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolemic patients: a randomized, double-blind study. J Cardiovasc Risk. 2001;8:383-90.
26. Shepherd J, Packard C, Smith K, et al. Evaluation of rosuvastatin in the treatment of hypercholesterolemia in postmenopausal women [abstract]. Atherosclerosis. 2002;3(suppl):205.
27. Marais D, Raal F, Stein E, et al. Effect of rosuvastatin on LDL-cholesterol, mevalonic acid, and other lipid measurements in patients with homozygous familial hypercholesterolemia [abstract]. Atherosclerosis. 2002;3(suppl):159.
28. Durrington P, Tuomilehto J, Hamann A, et al. Response to lipid-lowering treatment with rosuvastatin in diabetic patients with the metabolic syndrome [abstract]. Diabetic Med. 2003;20(suppl 2):100.
29. Ballantyne CM, Stein EA, Paoletti R, et al. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol. 2003;91(suppl):25C- 28C.
30. Blasetto JW, Stein EA, Brown WV, et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemia patients and in special population groups. Am J Cardiol. 2003;91(suppl):3C-10C.
31. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28:S4-S36.
32. Tuomilehto J. Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidemia. Diabetes Res Clin Pract. 2003;61:S27-S34.
33. Capuzzi DM, Morgan JM, Weiss RJ, et al. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol. 2003;91:1304-10.
34. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:567-72.
35. Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol. 2003;92(suppl):23K-29K.
36. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation. 2005;111:3051-7.
37. Grundy SM. The issue of statin safety: where do we stand [editorial]? Circulation. 2005;111:3016-9.
38. Department of Health and Human Service. Re: Docket No. 2004P-0113/CP1. Accessed at: www.fda.gov.cder/drug/infopage/rosuvastatin/crestor_CP.pdf, June 14, 2005.
39. Food and Drug Administration. FDA advisory committee meeting briefing document NDA 21-366 for the use of Crestor. June 11, 2003. Accessed at www.fda.gov/ohrms/dockets/ac/03/briefing/3968B1_02_A-FDA-Clinical%20Review.pdf, April 14, 2004.
40. Vidt D, Cressman M, Harris S, et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology. 2004;102:52-60.
41. Undas A, Brummel K, Musial J, et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001;103:2248-53.
42. Sever P, Dahlöf B, Paulter N, et al. for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2003;361:1149-55.
43. Cannon C, Braunwald E, McCabe C, et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504.